BridgeMD
New treatment option for Warm Autoimmune Hemolytic Anemia
Official title Sirolimus in the Treatment of Refractory/Relapsed wAIHA
ClinicalTrials.gov ID: NCT05925023
What this study is testing
What is Sirolimus?
Sirolimus is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for warm autoimmune hemolytic anemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Age ≥18 years old.
- Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic...
- No response to glucocorticoid therapy or recurrence.
- Baseline liver (ALT, AST) was less than 2 times the normal value.
- No active infection; Not pregnant or breastfeeding.
You likely can't join if
- Patients with connective tissue disease or other organs involvement
- Infection or bleeding that cannot be controlled by standard treatment.
- Active HIV, HCV or HBV infection or cirrhosis or portal hypertension.
- Progressed uncontrolled malignant tumors and lymphoma
- Cirrhosis or portal hypertension.
- Pregnant or breastfeeding.
See the full eligibility criteria
- Age ≥18 years old.
- Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic involvement in the original disease if secondary.
- No response to glucocorticoid therapy or recurrence.
- Baseline liver (ALT, AST) was less than 2 times the normal value.
- No active infection; Not pregnant or breastfeeding.
- Agree to sign the consent form.
- Patients with connective tissue disease or other organs involvement
- Infection or bleeding that cannot be controlled by standard treatment.
- Active HIV, HCV or HBV infection or cirrhosis or portal hypertension.
- Progressed uncontrolled malignant tumors and lymphoma
- Cirrhosis or portal hypertension.
- Pregnant or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.